Perspective Confidentiality Disclosure Reliability Courtesy
In Prostate Cancer: Three Nations, Several Distinctions, posted below, we see trans-national comparisons of African-Americans, European-Americans, Asian Indians, and Senegalese. Now a five-nation analysis focuses on prostate cancer incidence and mortality in the Nordic countries of Iceland, Norway, Sweden, Finland, and Denmark.
Filed under: Living with Prostate Cancer, Management, Treatment | 6 Comments »
We are delighted to see a recent paper by Zeigler-Johnson et al. address racial and geographic issues regarding prostate cancer in selected developing countries. While prostate cancer is common around the world, little is actually known about the presentation of the disease in West Africa and India compared to the United States.
Filed under: Diagnosis, Management, Prevention | 1 Comment »
Loeb et al. have published additional information in support of their argument that prostate-specific antigen velocity (PSAV) ”could be useful in treatment decision-making and in assessing the likelihood of long-term cancer control in men with prostate cancer.”
Filed under: Diagnosis, Management, Treatment | No Comments »
Dall’Era et al. have just reported their contemporary experience with active surveillance (AS) for prostate cancer in 321 men treated at the University of California San Francisco over the past 17 years.
Filed under: Management, Treatment | No Comments »
The “New” Prostate Cancer InfoLink is more than a little concerned by the implications of a recent review that compares outcomes of open (RRP), laparoscopic (LRP), and robotic assisted (RALP) prostatectomy.
Filed under: Management, Treatment | 3 Comments »
Skip Lockwood of the National Prostate Cancer Coalition is urgently looking for patients willing to discuss their personal stories with the American media. The gist of the story is the need for new diagnostics and the reporter is looking for patients who feel that they would have had better outcomes with better diagnostics like imaging [...]
Filed under: Uncategorized | Comments Off
A Canadian group has reported early results from the use of docetaxel + androgen deprivation therapy given prior to radical prostatectomy in an attempt to lower the risk of disease progression post-surgery in men with high-risk, localized prostate cancer.
Filed under: Drugs in development, Management, Treatment | No Comments »
A team at the Duke Prostate Center has just published data substantiating the continuing “stage migration” that has resulted from early detection of prostate cancer over the past 20 years. They go on to suggest that such stage migration may have future implications for therapy. “Stage migration” is a term used to describe the gradual and apparently [...]
Filed under: Management, Treatment | No Comments »
Many readers of this blog may be interested in learning a little more about the way medical device and pharmaceutical companies go about “marketing” clinical trials of new techniques and new drugs to the referring physician community and to the patient community. The current US trial of high-intensity focused ultrasound (HIFU) offers us an excellent [...]
Filed under: Drugs in development, Tips, Treatment | 4 Comments »
An article in the July issue of the Journal of Urology examines the relationship between hospital volume, surgeon volume (i.e., numbers of prostatectomies per year), and the number of deaths and in-hospital complications associated with 25,404 radical prostatectomies carried out in eight of the 10 Canadian provinces between 1990 and 2001. The clear result of this [...]
Filed under: Management, Treatment | No Comments »
